ZEPP
Zepp Health Corporation [ZEPP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ZEPP Stock Summary
Top 10 Correlated ETFs
ZEPP
Top 10 Correlated Stocks
ZEPP
In the News
ZEPP Financial details
Company Rating
Neutral
Market Cap
54.2M
Income
-275.98M
Revenue
2.97B
Book val./share
39.41
Cash/share
14.88
Dividend
-
Dividend %
-
Employees
987
Optionable
No
Shortable
Yes
Earnings
21 May 2024
P/E
-2.49
Forward P/E
-
PEG
0.06
P/S
0.23
P/B
0.27
P/C
0.06
P/FCF
5.93
Quick Ratio
1.25
Current Ratio
2.05
Debt / Equity
0.57
LT Debt / Equity
0.35
-
-
EPS (TTM)
-4.55
EPS next Y
-
EPS next Q
-
EPS this Y
-427.63%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
2.59%
Revenue Q/Q
-7.13%
EPS Q/Q
-103.45%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
13.37%
Inst Trans
0.92%
ROA
-6%
ROE
-11%
ROC
-0.08%
Gross Margin
23%
Oper. Margin
-10%
Profit Margin
-9%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.9-2.1
52W High
-
52W Low
-
RSI
30
Rel Volume
0.32
Avg Volume
68.92K
Volume
22.21K
Perf Week
-8.79%
Perf Month
-27.59%
Perf Quarter
-16.27%
Perf Half Y
-24.32%
-
-
-
-
Beta
0.845
-
-
Volatility
0.03%, 0.12%
Prev Close
1.69%
Price
0.84
Change
1.2%
ZEPP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 65.17 | 95.42 | 103.57 | 99.14 | 67.29 | |
| Net income per share | 6.08 | 9.44 | 3.68 | 1.52 | -4.98 | |
| Operating cash flow per share | 12.65 | 7.03 | 2.53 | -3.69 | -12.79 | |
| Free cash flow per share | 11.41 | 6.27 | 1.17 | -4.53 | -12.95 | |
| Cash per share | 28.41 | 29.88 | 36.97 | 23.68 | 14.96 | |
| Book value per share | 32.37 | 41.06 | 43.95 | 46.32 | 43.41 | |
| Tangible book value per share | 31.1 | 39.5 | 40.61 | 43.41 | 40.53 | |
| Share holders equity per share | 32.37 | 41.06 | 43.95 | 46.32 | 43.41 | |
| Interest debt per share | 0.7 | 1.83 | 11.33 | 20.69 | 28.28 | |
| Market cap | 3.66B | 4.93B | 4.65B | 2.03B | 615.72M | |
| Enterprise value | 2.26B | 3.24B | 3.06B | 1.82B | 1.41B | |
| P/E ratio | 10.76 | 8.57 | 20.32 | 21.15 | -2.01 | |
| Price to sales ratio | 1 | 0.85 | 0.72 | 0.32 | 0.15 | |
| POCF ratio | 5.17 | 11.52 | 29.55 | -8.73 | -0.78 | |
| PFCF ratio | 5.73 | 12.91 | 64.08 | -7.11 | -0.77 | |
| P/B Ratio | 2.02 | 1.97 | 1.7 | 0.69 | 0.23 | |
| PTB ratio | 2.02 | 1.97 | 1.7 | 0.69 | 0.23 | |
| EV to sales | 0.62 | 0.56 | 0.47 | 0.29 | 0.34 | |
| Enterprise value over EBITDA | 6.31 | 5.36 | 29 | 12.01 | -3.99 | |
| EV to operating cash flow | 3.19 | 7.57 | 19.42 | -7.83 | -1.79 | |
| EV to free cash flow | 3.53 | 8.48 | 42.13 | -6.37 | -1.77 | |
| Earnings yield | 0.09 | 0.12 | 0.05 | 0.05 | -0.5 | |
| Free cash flow yield | 0.17 | 0.08 | 0.02 | -0.14 | -1.3 | |
| Debt to equity | 0.02 | 0.04 | 0.25 | 0.43 | 0.63 | |
| Debt to assets | 0.01 | 0.02 | 0.12 | 0.21 | 0.32 | |
| Net debt to EBITDA | -3.92 | -2.8 | -15.12 | -1.38 | -2.25 | |
| Current ratio | 2.06 | 1.77 | 1.73 | 1.83 | 1.77 | |
| Interest coverage | 0 | 0 | 3.46 | 2.09 | -7.2 | |
| Income quality | 2.1 | 0.75 | 0.68 | -1.7 | 2.73 | |
| Dividend Yield | 0.06 | 0 | 0 | 0 | 0.06 | |
| Payout ratio | 0.62 | 0.01 | 0 | 0 | -0.13 | |
| Sales general and administrative to revenue | 0.06 | 0.04 | 0.04 | 0.04 | 0.06 | |
| Research and developement to revenue | 0.07 | 0.07 | 0.08 | 0.08 | 0.12 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.04 | 0.03 | 0.04 | |
| Capex to operating cash flow | -0.1 | -0.11 | -0.54 | 0.23 | 0.01 | |
| Capex to revenue | -0.02 | -0.01 | -0.01 | -0.01 | 0 | |
| Capex to depreciation | -11.13 | -2.68 | -3.12 | -1.02 | -0.17 | |
| Stock based compensation to revenue | 0.04 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham number | 66.54 | 93.4 | 60.35 | 39.82 | 69.74 | |
| ROIC | 0.17 | 0.2 | 0.02 | 0.02 | -0.08 | |
| Return on tangible assets | 0.11 | 0.11 | 0.04 | 0.02 | -0.06 | |
| Graham Net | 16.43 | 13.09 | 9.67 | -6.5 | -8.69 | |
| Working capital | 1.47B | 1.91B | 2.04B | 1.78B | 1.29B | |
| Tangible asset value | 1.74B | 2.41B | 2.52B | 2.74B | 2.5B | |
| Net current asset value | 1.41B | 1.72B | 1.65B | 778.89M | 375.83M | |
| Invested capital | 0.02 | 0.04 | 0.25 | 0.43 | 0.63 | |
| Average receivables | 0 | 1.16B | 1.38B | 995.47M | 826.71M | |
| Average payables | 0 | 1.53B | 1.98B | 1.63B | 890.79M | |
| Average inventory | 0 | 689.21M | 1.06B | 1.23B | 1.14B | |
| Days sales outstanding | 71.62 | 101.11 | 65.71 | 48.63 | 72.31 | |
| Days payables outstanding | 143.54 | 168.02 | 139.64 | 97.24 | 50.74 | |
| Days of inventory on hand | 65.37 | 75.09 | 87.13 | 92.23 | 111.69 | |
| Receivables turnover | 5.1 | 3.61 | 5.55 | 7.51 | 5.05 | |
| Payables turnover | 2.54 | 2.17 | 2.61 | 3.75 | 7.19 | |
| Inventory turnover | 5.58 | 4.86 | 4.19 | 3.96 | 3.27 | |
| ROE | 0.19 | 0.23 | 0.08 | 0.03 | -0.11 | |
| Capex per share | -1.24 | -0.76 | -1.36 | -0.84 | -0.16 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 19.76 | 17.6 | 10.57 | 10.75 | 9.4 | |
| Net income per share | -0.34 | -1.23 | -2.2 | -1.16 | 0.05 | |
| Operating cash flow per share | 0 | 1.61 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 1.92 | 0 | 0 | 0 | |
| Cash per share | 16.11 | 15.12 | 16.32 | 17.33 | 14.88 | |
| Book value per share | 45.4 | 43.88 | 41.69 | 41.56 | 39.41 | |
| Tangible book value per share | 42.38 | 40.98 | 38.86 | 38.8 | 36.87 | |
| Share holders equity per share | 45.4 | 43.88 | 41.69 | 41.56 | 39.41 | |
| Interest debt per share | 28.1 | 27.92 | 26.59 | 26.29 | 22.71 | |
| Market cap | 595.69M | 609.04M | 549.34M | 498.45M | 537.67M | |
| Enterprise value | 1.36B | 1.41B | 1.2B | 1.06B | 1.06B | |
| P/E ratio | -7.22 | -2.03 | -1.03 | -1.78 | 45.18 | |
| Price to sales ratio | 0.49 | 0.57 | 0.85 | 0.77 | 0.89 | |
| POCF ratio | 0 | 6.22 | 0 | 0 | 0 | |
| PFCF ratio | 0 | 5.2 | 0 | 0 | 0 | |
| P/B Ratio | 0.21 | 0.23 | 0.22 | 0.2 | 0.21 | |
| PTB ratio | 0.21 | 0.23 | 0.22 | 0.2 | 0.21 | |
| EV to sales | 1.12 | 1.31 | 1.86 | 1.64 | 1.76 | |
| Enterprise value over EBITDA | -42.73 | -20.97 | -8.08 | -15.81 | 70.53 | |
| EV to operating cash flow | 0 | 14.37 | 0 | 0 | 0 | |
| EV to free cash flow | 0 | 12.01 | 0 | 0 | 0 | |
| Earnings yield | -0.03 | -0.12 | -0.24 | -0.14 | 0.01 | |
| Free cash flow yield | 0 | 0.19 | 0 | 0 | 0 | |
| Debt to equity | 0.61 | 0.63 | 0.63 | 0.63 | 0.57 | |
| Debt to assets | 0.29 | 0.32 | 0.33 | 0.32 | 0.3 | |
| Net debt to EBITDA | -23.95 | -11.89 | -4.39 | -8.39 | 34.66 | |
| Current ratio | 1.65 | 1.77 | 2.16 | 1.92 | 2.05 | |
| Interest coverage | -4.85 | -4.4 | -11.33 | -5.88 | 0.93 | |
| Income quality | 0 | -9.22 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.04 | 0.05 | 0.08 | 0.08 | 0.08 | |
| Research and developement to revenue | 0.11 | 0.11 | 0.18 | 0.14 | 0.12 | |
| Intangibles to total assets | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | |
| Capex to operating cash flow | 0 | 0.2 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0.02 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | -15.63 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | -0.01 | 0 | 0 | 0 | |
| Graham number | 18.58 | 34.88 | 45.38 | 32.93 | 6.42 | |
| ROIC | -0.01 | -0.02 | -0.03 | -0.01 | 0 | |
| Return on tangible assets | 0 | -0.01 | -0.03 | -0.01 | 0 | |
| Graham Net | -11.86 | -8.79 | -7.79 | -8.51 | -8.07 | |
| Working capital | 1.36B | 1.29B | 1.39B | 1.25B | 1.28B | |
| Tangible asset value | 2.59B | 2.5B | 2.37B | 2.34B | 2.36B | |
| Net current asset value | 418.71M | 375.83M | 252.91M | 199.85M | 207.13M | |
| Invested capital | 0.61 | 0.63 | 0.63 | 0.63 | 0.57 | |
| Average receivables | 976.76M | 838.8M | 723.84M | 635.44M | 611.42M | |
| Average payables | 873.1M | 633.93M | 399.99M | 387.8M | 440.39M | |
| Average inventory | 1.45B | 1.2B | 910.93M | 771.25M | 764.77M | |
| Days sales outstanding | 63.96 | 68.92 | 87.46 | 89.38 | 86.54 | |
| Days payables outstanding | 74.17 | 49.17 | 55.71 | 78.27 | 99.69 | |
| Days of inventory on hand | 126.92 | 108.22 | 132.75 | 132.13 | 177.95 | |
| Receivables turnover | 1.41 | 1.31 | 1.03 | 1.01 | 1.04 | |
| Payables turnover | 1.21 | 1.83 | 1.62 | 1.15 | 0.9 | |
| Inventory turnover | 0.71 | 0.83 | 0.68 | 0.68 | 0.51 | |
| ROE | -0.01 | -0.03 | -0.05 | -0.03 | 0 | |
| Capex per share | 0 | 0.32 | 0 | 0 | 0 |
ZEPP Frequently Asked Questions
What is Zepp Health Corporation stock symbol ?
Zepp Health Corporation is a CN stock and trading under the symbol ZEPP
What is Zepp Health Corporation stock quote today ?
Zepp Health Corporation stock price is $0.84 today.
Is Zepp Health Corporation stock public?
Yes, Zepp Health Corporation is a publicly traded company.
Company Profile
- Volume Average 68.92K
- Market Capitalization 54.2M
- Employee 987
- CEO Mr. Meihui Fan
- Headquarters Hefei,CN
- IPO Date 2018-02-08
-
Website
https://www.huami.com 
Zepp Health Corporation, together with its subsidiaries, develops, manufactures, and sells smart wearable technological devices in the People's Republic of China. It operates through two segments, Xiaomi Wearable Products, and Self-Branded Products and Others. The company offers smart bands, watches, and scales; and smart hearable products, home treadmill, sportswear, home appliances, and smart watch accessories under the Xiaomi and Amazfit brands. It provides charts and graphs to display analysis of the activity and biometric data collected from users through its Zepp Life and Zepp mobile apps. The company was formerly known as Huami Corporation and changed its name to Zepp Health Corporation in February 2021. Zepp Health Corporation was founded in 2013 and is headquartered in Hefei, the People's Republic of China.
